Dr. Wu is a Postdoctoral Research Fellow at Dana-Farber Cancer Institute, Harvard Medical School in Boston. After receiving his Ph.D. from the University of Science and Technology of China, China, he made a decision to focus on cancer research and translate mechanistic findings into clinical therapies and joined the lab of David Weinstock, MD, whose contributions have made a significant impact in hematological malignancies. Non-Hodgkin lymphoma patients with TP63-rearrangements, which are a kind of mutation in gene TP63, have dismal outcomes, with 0-17% of patients surviving 5 years after diagnosis, depending on the lymphoma subtypes. Dr. Wu’s LLS research project is focused on clarifying the oncogenic role of TP63-rearrangements in lymphoma initiation and progression and developing new treatment options for these patients. These studies are aligned with his central career goal, which is to leverage mechanistic insights to improve the outcomes for patients with lymphomas that harbor high-risk genetic alterations.